メニュー
Target safety assessment including known toxicities, essentiality, and off-target concerns. Use for early safety risk evaluation and target selection. Keywords: target safety, toxicity, essential gene, knockout, safety risks
デフォルトでは、最初にソースを確認する Prompt が選択されています。直接コマンドに切り替えるか、ローカルコピーをダウンロードすることもできます。
インストールを決める前に、SKILL.md と SkillsMP に表示されている付属ファイルをお読みください。
Codex または Claude でインストール この Prompt をコピーして Codex、Claude、または他のアシスタントに貼り付けると、Skill ページを確認してインストールできます。
直接コマンドでは確認用 Prompt が省略されます。実行前にソースを確認してください。
npx skills add https://github.com/huifer/drug-discovery-skills --skill target-safetyコマンドは1行のまま表示されます。コピー前に横へスクロールして全体を確認してください。
ローカルで確認しますか？SkillsMP が現在取得できるファイルをダウンロードできます。
Global drug development pipeline tracking by disease, target, mechanism, or company. Use for competitive intelligence, opportunity identification, and trend analysis. Keywords: pipeline, drug development, clinical trials, R&D tracking, competitive landscape
Structure-based similarity search and scaffold analysis for drug discovery. Use for lead hopping, scaffold morphing, and chemical space exploration. Keywords: similarity search, scaffold hopping, chemical space, fingerprint, Tanimoto
Analyze target competitive landscape including existing drugs, pipeline companies, differentiation opportunities, and market maturity assessment. Keywords: target competition, landscape, differentiation, pipeline analysis, market share
SOC 職業分類に基づく
SKILL.md を表示中
| name | target-safety |
| description | Target safety assessment including known toxicities, essentiality, and off-target concerns. Use for early safety risk evaluation and target selection. Keywords: target safety, toxicity, essential gene, knockout, safety risks |
| category | Target Safety |
| tags | ["safety","toxicity","essentiality","knockout","risk-assessment"] |
| version | 1.0.0 |
| author | Drug Discovery Team |
| dependencies | ["imap-database","gwas-catalog","clinvar","essential-genes"] |
Assess target safety before investing in drug development.
/target-safety EGFR --full
/safety "BCR-ABL" --include knockout,expression
/essentiality-check --target "KRAS" --species human,mouse
| Category | Description | Impact |
|---|---|---|
| Essentiality | Gene required for survival | High |
| Knockout phenotypes | Animal model effects | Medium |
| Human genetics | Disease associations | Medium |
| Pathway crosstalk | Off-target effects | Medium |
| Tissue expression | Safety biomarkers | Low |
# Target Safety Assessment: EGFR
## Summary
| Concern | Level | Impact |
|---------|-------|--------|
| Essentiality | Medium | Manageable |
| Knockout effects | High | Monitor |
| Human genetics | Low | Not concerning |
| Off-target | Medium | Selectivity needed |
**Overall Risk**: Medium - Proceed with safety monitoring
## Essentiality Analysis
### Gene Essentiality
| Species | Essential | Phenotype |
|---------|-----------|----------|
| Human | Likely | Haploinsufficiency possible |
| Mouse | Yes | Embryonic lethal (homozygous) |
| Rat | Yes | Growth defects |
### Human Genetic Data
| Variant | Effect | Frequency | Condition |
|--------|--------|-----------|----------|
| Loss-of-function | Tolerated | Common | Population variants |
| Gain-of-function | Pathogenic | Rare | Cancer syndromes |
**Interpretation**: Heterozygous tolerance observed - manageable risk
## Knockout Phenotypes
### Mouse Models
| Genotype | Viable | Phenotype | Severity |
|----------|--------|----------|----------|
| +/+ | Yes | Normal | - |
| +/- | Yes | Skin defects, hair loss | Medium |
| -/- | No | Embryonic lethal | High |
**Key Findings**:
- Heterozygous viable with mild phenotypes
- Skin-related effects expected
- Dose-dependent toxicity likely
## Tissue Expression
### Expression Profile
| Tissue | Expression Level | Safety Concern |
|--------|-----------------|----------------|
| Skin | High | High (rash, acne) |
| Lung | Medium | Medium (interstitial lung disease) |
| GI Tract | Medium | Medium (diarrhea) |
| Liver | Low | Low |
| Heart | Low | Low |
| CNS | Low | Low |
**Safety Biomarkers**: Skin toxicity, lung function
## Known Safety Issues
### Approved EGFR Inhibitors
| Drug | Safety Issue | Incidence | Management |
|------|---------------|-----------|------------|
| Erlotinib | Rash | 70% | Topical steroids |
| Erlotinib | Diarrhea | 50% | Loperamide |
| Osimertinib | ILD | 3% | Steroids, discontinuation |
| Osimertinib | Cardiac | 2% | Monitoring |
**Class Effects**:
- Skin toxicity (nearly universal)
- GI effects (common)
- Interstitial lung disease (rare but serious)
: Start low, go slow
: PK-guided dosing
: Skin assessment, pulmonary function
: Exclude pre-existing conditions
: Pre-emptive skin care
| Target | Safety Profile | Comparable Issues |
|--------|-----------------|-------------------|
| EGFR | Medium | Skin, lung |
| HER2 | Medium | Cardiac |
| VEGFR | High | Hypertension, proteinuria |
| MET | Medium | Edema |
: Use relevant species
: Focus on skin, lung, cardiac
: Skin histopathology
: Maximum recommended starting dose
: Conservative (1/10 STD10)
: Include PK/PD modeling
:
Daily skin assessment (first cycle)
Baseline and periodic pulmonary function
ECG monitoring
Liver function tests
:
Grade 3+ rash >14 days
Any Grade 2+ ILD
Unresolved diarrhea >14 days
| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| Skin toxicity | High | Medium | Proactive management |
| ILD | Low | High | Monitoring, early detection |
| Diarrhea | High | Low | Standard supportive care |
| Cardiac | Low | Medium | ECG monitoring |
| Hepatotoxicity | Low | Medium | LFT monitoring |